# CISPD-1 (NCT03750669)

> Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer

No report yet. It can be ordered.

- Drugs tested: AG plus mFOLFIRINOX
- Indication: resectable pancreatic cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03750669
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
- Conditions: Pancreatic Adenocarcinoma Resectable; Neoadjuvant Chemotherapy
- Interventions: AG regimen; mFolfirinox
- Enrollment: 324
- Primary outcome: event-free survival (EFS)

## Indexed commentary on CISPD-1 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=cispd-1-nct03750669